TY - JOUR
T1 - Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection
AU - Giraldo, Manuel A.
AU - Arevalo-Pinzon, Gabriela
AU - Rojas-Caraballo, Jose
AU - Mongui, Alvaro
AU - Rodriguez, Raul
AU - Patarroyo, Manuel A.
N1 - Funding Information:
This project was financed by COLCIENCIAS contract RC-528-2008. Special thanks go to the veterinary and animal care staff at FIDIC's primate station in Leticia, Amazonas, Colombia, for providing excellent animal care. We would like to thank Diana Millán Cortes for her technical assistance with molecular assays and Nora Martinez for her assistance in the translation of the manuscript. We are greatly indebted to Prof. Manuel Elkin Patarroyo for his valuable comments to the manuscript.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009/12/10
Y1 - 2009/12/10
N2 - Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. High antigenicity was observed since sera from P. vivax-infected patients strongly recognized rPvMSP10. The immunogenicity of rPvMSP10 was tested in Aotus monkeys, comparing responses induced by formulations with Freund's adjuvant, Montanide ISA720 or aluminum hydroxide. All formulations produced high antibody titers recognizing the native protein in late schizonts. Despite inducing strong antibody production, none of the formulations protected immunized Aotus monkeys upon experimental challenge.
AB - Although largely considered benign, Plasmodium vivax causes disease in nearly 75 million people each year and the available strategies are not sufficient to reduce the burden of disease, therefore pointing to vaccine development as a cost-effective control measure. In this study, the P. vivax merozoite surface protein 10 (MSP-10) was expressed as a recombinant protein in Escherichia coli and purified by affinity chromatography. High antigenicity was observed since sera from P. vivax-infected patients strongly recognized rPvMSP10. The immunogenicity of rPvMSP10 was tested in Aotus monkeys, comparing responses induced by formulations with Freund's adjuvant, Montanide ISA720 or aluminum hydroxide. All formulations produced high antibody titers recognizing the native protein in late schizonts. Despite inducing strong antibody production, none of the formulations protected immunized Aotus monkeys upon experimental challenge.
UR - http://www.scopus.com/inward/record.url?scp=70649115450&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70649115450&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2009.09.046
DO - 10.1016/j.vaccine.2009.09.046
M3 - Research Article
C2 - 19782110
AN - SCOPUS:70649115450
SN - 0264-410X
VL - 28
SP - 7
EP - 13
JO - Vaccine
JF - Vaccine
IS - 1
ER -
